

SOP40104: Cryopreservation of Patient-Derived Organoid (PDOrg) Cultures		
Patient Derived Models Repository: In vitro Lab		
Revision Date:	2/20/2019	Page 1 of 10

## Table of Contents

CHANGE HISTORY .....	1
RELATED SOPS .....	1
1.0 PURPOSE/SCOPE .....	2
2.0 SAFETY .....	2
3.0 CLEAN-UP .....	2
4.0 REAGENTS AND EQUIPMENT .....	3
5.0 PROCEDURE .....	5
6.0 CRYOPRESERVATION OF PATIENT-DERIVED ORGANIDS .....	7
7.0 RECOMMENDED QUALITY CONTROL .....	8
8.0 REFERENCES .....	8
APPENDIX 1: FIGURES .....	9

## CHANGE HISTORY

Revision	Description
8/25/2017, v003	Internal SOP used by PDMR In Vitro Laboratory
2/13/2018	Standardize SOP for posting to PDMR SharePoint site for use by designated NCI intramural laboratories
2/20/2019	Updated reference SOPs.

## RELATED SOPS

SOP30101: Recipes for Complete Media for Patient-Derived In Vitro and Organoid Cultures
SOP40102: Thawing and Initial Culture of Patient-Derived Organoid (PDOrg) Cultures
SOP40103: Passaging and Sub-culture of Patient-Derived Organoid (PDOrg) Cultures

SOP40104: Cryopreservation of Patient-Derived Organoid (PDOrg) Cultures		
Patient Derived Models Repository: In vitro Lab		
Revision Date:	2/20/2019	Page 2 of 10

## 1.0 PURPOSE/SCOPE

This Standing Operating Procedure (SOP) describes the procedures for passaging of Patient-Derived organoid cultures (PDOrg) under BSL-2 safety criteria. Optimal tissue culture media for use with specific PDOrg lines will be provided with the individual **Certificate of Analysis**. This SOP is used/performed by the Biological Testing Branch (BTB) at NCI-Frederick, Frederick National Laboratory for Cancer Research.

## 2.0 SAFETY

BTB treats all patient-derived material under Biosafety Level 2 (BSL2) conditions even when PCR-based screening has not detected the presence of a known set of human pathogens. All work is conducted in a biological safety cabinet (BSC) using personal protective equipment and avoiding the use of sharps where possible. All materials potentially exposed to human-derived material are disinfected by exposure to a 10% bleach solution for a minimum of 10 minutes, double bagging for autoclaving or incineration. Consult with your facility safety professionals regarding the safe handling of BSL2 studies.

## 3.0 CLEAN-UP

- 3.1 All materials coming into contact with human-derived material are treated as a potential health threat (BSL-2 precautions) since the human-derived materials could retain human pathogenic agents even if they do not replicate in mouse cells (e.g., EBV, HPV, etc).
- 3.2 Flush/soak any items (e.g., tubes, syringes, petri dishes, lab mats, etc) that were in contact with human-derived material with disinfectant (e.g., 10% bleach, commercial hydrogen peroxide disinfectant, 2% Virkon®) for a minimum of 10 minutes before disposal in biohazard waste or sharps containers (follow institutional guidelines and manufacturer's recommendations).
- 3.3 For items that can't be rinsed (e.g., micropipettors), wipe down thoroughly with bleach-soaked gauze or other appropriate disinfectants.

## 4.0 REAGENTS AND EQUIPMENT

### 4.1 Certificate of Analysis for PDOrg culture

### 4.2 Wash Media:

Item	Catalog	Volume
Basic Media	*see SOP30101	100 mL
FBS	HyClone Laboratories, Cat#: SH30071.03HI	2.5 mL

**4.2.1** Sterile filter with 0.22 µm filter. Prepare fresh weekly and warm to room temperature 2-3 hours before use.

### 4.3 Reagents, Material & Equipment

**4.3.1** Dispase II (Thermo Fisher Scientific, Cat#: 17105-041)

**4.3.2** Advanced DMEM/F12 (1X) (Invitrogen, Cat#: 12634-028)

**4.3.3** TrypLE™ Express Enzyme (1X), phenol red (Thermo Fisher Scientific, Cat#: 12605010)

**4.3.4** Fetal Bovine Serum (FBS; HyClone Laboratories, Cat#: SH30071.03HI)

**4.3.5** Hydrocortisone (Sigma, Cat#: H4001-1G)

**4.3.6** Ethanol, 200 Proof, 99.98% (e.g., Pharmco-Aaper, Cat#: 111000200CSPP)

**4.3.7** EGF Recombinant Human Protein (hEGF; Invitrogen, Cat#: PHG0311 or R&D Systems, Cat#: AFL236)

**4.3.8** DPBS, no calcium, no magnesium (Thermo Fisher Scientific, Cat#: 14190250)

**4.3.9** Adenine (Sigma, Cat#: A2786)

**4.3.10** Hydrochloric acid, HCl (e.g., Sigma-Aldrich, Cat#: 320331-500mL)

**4.3.11** Penicillin-Streptomycin (10,000 U/mL, Thermo Fisher Scientific, Cat#: 15140163)

**4.3.12** L-Glutamine (200mM, Thermo Fischer Scientific, Cat#: 25030-081)

**4.3.13** DMSO, HPLC-grade, >99.5% pure (Honeywell Research Chemicals/Burdick & Jackson, Cat#: 081-1L)

**4.3.14** Sterile, 0.22 µm Filter Units (e.g., Millipore-Sigma, Cat#: SCGPU05RE)

**4.3.15** P1000, P200 and P20 Pipetman (or equivalent) and tips

**4.3.16** 50-mL sterile conical tubes, sterile

**4.3.17** 5, 10, 25 mL pipettes and automatic pipettor

**4.3.18** Aspirator pipettes (e.g., Fisher Scientific, Cat#: 357501)

SOP40104: Cryopreservation of Patient-Derived Organoid (PDOrg) Cultures		
Patient Derived Models Repository: In vitro Lab		
Revision Date:	2/20/2019	Page 4 of 10

**4.3.19** Cryovials, screw-capped, sterile, 1.8-2.0 mL capacity (Nunc, Cat#: 368632)

**4.3.20** Ice bucket with ice

**4.3.21** Benchtop Centrifuge equipped with sealed buckets

**4.3.22** Biosafety Level 2 certified biosafety cabinet

**4.3.23** 37°C humidified, 5% CO<sub>2</sub> tissue culture incubator

**4.3.24** 37°C shaker-incubator

## 5.0 PROCEDURE

### 5.1 Guidance on Cryopreservation Timing

**5.1.1** Organoids are ready to be cryopreserved based on 2 criteria: **density and size.**

**5.1.1.1** **High-density Organoid Cultures:** [Figure 1](#) and [Figure 2](#): Left panels: Example of PDOrg cultures at high density when cryopreservation can occur.

**5.1.1.2** **Low-density Cultures:** [Figure 1](#) and [Figure 2](#): Right panels: Example of PDOrg cultures at low density when feeding is all that is required. As described in **SOP40103: Passaging and Sub-culture of Patient-Derived Organoid (PDOrg) Cultures** SOP Step 5.1.1.2, low density cultures should not be cryopreserved. Follow recommendations in that SOP for passaging to increase the density of the culture.

### 5.2 Prepare Reagents

**5.2.1** Before starting, prepare Splitting Media: 1.5 mg/mL Dispase II in Wash Media, sterile filter with 0.22 µm filter, and store on ice. Should be prepared fresh each week, store at 4°C.

#### 5.2.2 Prepare Freeze Media

**5.2.2.1** Prepare the following solution and sterile filter using a 0.22 µm filter.

Item	Stock Concentration	Volume
Advanced DMEM/F12		500mL
FBS		100 mL
Hydrocortisone	1 mg/mL in 20% EtOH	200 µL
hEGF	50 µg/mL in DPBS	5 µL
Adenine	2.4mg/mL in 0.05M HCL	5 mL
Penicillin-Streptomycin	10,000 U/mL	5 mL
L-Glutamine	200 mM	5 mL

**5.2.2.2** Add 68.5 mL DMSO to filtered solution to make Freeze Media. Keep Freeze Media on ice.

**5.2.2.3** Prepare Freeze Media fresh each week and store at 4°C.

**5.2.3** Have Cryovials labeled with the model name, passage number, and freeze date.

**5.2.4** Perform all procedures under sterile conditions in a Biosafety Level 2 certified biosafety cabinet.

SOP40104: Cryopreservation of Patient-Derived Organoid (PDOrg) Cultures		
Patient Derived Models Repository: In vitro Lab		
Revision Date:	2/20/2019	Page 6 of 10

### 5.3 Passaging Organoid Cultures

The NCI PDMR generally cryopreserves 7-9 dense 24-well plates.

While this varies model-to-model, an average of 30 cryopreserved vials at  $1-6 \times 10^6$  cells per vial can be prepared from this.

- 5.3.1 Add a volume of Splitting Media equal to the volume of Feeding Media present in each well to be cryopreserved. This provides a final concentration of Dispase II at 0.75 mg/mL. For a single well in a 24-well plate, this would be 750  $\mu$ L Splitting Media per well to the already present 750  $\mu$ L Feeding Media.
- 5.3.2 Place the plate with the Splitting Media in a 37°C tissue culture incubator and incubate for 1.5 to 2 hours.
- 5.3.3 Using a P1000 Pipetman, gently pipette up and down the Splitting Media in each well to dissociate any residual BME dome.
- 5.3.4 Transfer the dissociated BME2 domes, organoids, and Splitting Media into a sterile 50-mL conical tube and add an equal volume Wash Media to dilute and neutralize the Dispase II.
- 5.3.5 Centrifuge the organoid solution at 200xg for 5 min.
- 5.3.6 With a 10-mL pipette, remove as much Splitting/Wash Media as possible.
- 5.3.7 Add Wash Media. The volume will depend on the size of the pellet. For example, if the pellet size is approximately 2 mL, add 50 mL Wash Media. Resuspend the organoids by mildly pipetting up and down. The goal is to keep the organoids intact in the suspension.
- 5.3.8 Count the viable cells present in the organoid suspension as follows
  - 5.3.8.1 Gently mix the organoid suspension to be sure everything is evenly mixed, then pipette a 50-100  $\mu$ L aliquot of organoid suspension to an Eppendorf tube and add the same volume of TrypLE Express. Keep the organoid suspension on ice.
  - 5.3.8.2 Counting should be done using dissociated single cells.
    - Disassociate to single cells by placing the aliquot of organoids/TrypLE Express in a 37°C shaker-incubator for 5 minutes.
    - After 5 min at 37°C, pipette the suspension up and down to fully suspend to single cells.
  - 5.3.8.3 Follow manufacturer's instructions for counting viable cells and determine the viable cell number in the original organoid suspension.
  - 5.3.8.4 Once the cell number has been determined discard the tube. **DO NOT** add the dissociated cells back to the tube containing the intact organoids.
- 5.3.9 Centrifuge the intact organoid suspension at 200xg for 5 min.

SOP40104: Cryopreservation of Patient-Derived Organoid (PDOrg) Cultures		
Patient Derived Models Repository: In vitro Lab		
Revision Date:	2/20/2019	Page 7 of 10

#### 5.4 Prepare Cryo Aliquots

- 5.4.1 With a pipette, carefully remove as much Wash Media as possible from the pellet.
- 5.4.2 Add chilled Freeze Media to the tube so that the final cell concentration is **1-6x10<sup>6</sup> viable cells/mL**. Gently pipette up and down. The goal is to keep the organoids intact in the suspension.
- 5.4.3 Keep organoid/Freezing Media suspension 50-mL tube on ice.
- 5.4.4 Have labeled cryovials in a tube rack with caps loosened for aliquoting.
- 5.4.5 Using a 5-mL pipette, aliquot three 1-mL aliquots of organoid/Freezing Media suspension into the pre-labeled cryovials.
  - **IMPORTANT:** Prior to each aliquot, gently mix the organoid/Freezing Media suspension as the organoids settle quickly to the bottom of the tube.
  - We find use of a 5-mL pipette for mixing and preparing three 1-mL aliquots results in a more uniform number of organoids/cryovial and reduces the number of organoids adhering to the pipet wall.
- 5.4.6 Apply the cap to the cryovials, seal well. Wipe the exterior with disinfectant then place directly into isopropanol-based slow-rate freezing container (e.g., Mr. Frosty) and place into -80°C immediately. Additional details below.

### 6.0 CRYOPRESERVATION OF PATIENT-DERIVED ORGANOID

- 6.1 We strongly recommend cryopreserving one model at a time and placing the aliquots into a slow-rate freezing container and then -80°C as quickly as possible.
- 6.2 Slow-rate freezing (isopropanol-based using a cryo 1°C cell-freezing container such as Mr. Frosty Freeze Container [Sigma-Aldrich, Cat#: C1562])
  - 6.2.1 Follow the manufacturer's instructions as provided for the specific cryopreservation device.
    - 6.2.1.1 The base of the cryo-container is filled with room temperature isopropanol per the manufacturer's recommendation and the tube holder is placed on top.
    - 6.2.1.2 Transfer the cryovials filled with organoids/freeze media into the tube holder of the cryo-container, screw the lid securely onto the cryo-container, and place at -80°C overnight.
    - 6.2.1.3 Vials should be transferred to the vapor phase of a liquid nitrogen tank as soon as practical after the 4-hr freeze step, typically the following morning. In no case, should the vials be held longer than 3 days at -80°C before transfer into the vapor phase of a liquid nitrogen storage tank.

SOP40104: Cryopreservation of Patient-Derived Organoid (PDOrg) Cultures		
Patient Derived Models Repository: In vitro Lab		
Revision Date:	2/20/2019	Page 8 of 10

## 7.0 RECOMMENDED QUALITY CONTROL

- 7.1 Maintain a record of reagents used to prepare media.
- 7.2 Document vendors and lot numbers of all media components.
- 7.3 At change-over, parallel new reagents with existing lots prior to placing a new lot into service.


## 8.0 REFERENCES

- Sato, T., et al., *Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium*. Gastroenterology, 2011. **141**(5): p. 1762-72.  
<https://www.ncbi.nlm.nih.gov/pubmed/21889923>
- Tuveson Laboratory Protocols, Cold Spring Harbor Laboratory. *Murine and Human Organoid Protocols* (Version: 4/27/2016). Link to protocol:  
<http://tuvesonlab.labsites.cshl.edu/wp-content/uploads/sites/49/2017/01/20160427-TuvesonOrganoidProtocols.pdf>

SOP40104: Cryopreservation of Patient-Derived Organoid (PDOrg) Cultures		
Patient Derived Models Repository: In vitro Lab		
Revision Date:	2/20/2019	Page 9 of 10

## APPENDIX 1: FIGURES

**Figure 1:** Example #1 - High (left) and low (right) density PDOrg cultures



SOP40104: Cryopreservation of Patient-Derived Organoid (PDOrg) Cultures		
Patient Derived Models Repository: In vitro Lab		
Revision Date:	2/20/2019	Page 10 of 10

**Figure 2:** Example #2 - High (left) and low (right) density PDOrg cultures

